Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Exploration of Brain Functional Networks in Patients With Hidradenitis Suppurativa Using fMRI

4. august 2026 oppdatert av: Second Xiangya Hospital of Central South University

The goal of this observational study is to learn whether adults with hidradenitis suppurativa (HS) have changes in resting brain activity and how these changes are related to disease severity, pain, sleep, mood, and quality of life. The study will also examine whether brain activity changes after patients receive biologic or small-molecule treatment as part of their regular medical care.

The main questions it aims to answer are:

  • Are resting brain activity patterns different between people with HS and healthy participants?
  • Are these brain activity patterns related to HS severity, pain, sleep problems, anxiety, depression, and quality of life?
  • Do brain activity patterns change after 3 months of routine treatment, and are these changes related to improvement in HS symptoms? Researchers will compare participants with HS with healthy participants of similar age and sex. A subgroup of participants with HS who receive biologic or small-molecule treatment as part of routine clinical care will also be assessed before and after treatment.

Participants may:

  • Complete assessments of HS severity, pain, sleep, mood, and quality of life
  • Undergo resting-state functional magnetic resonance imaging
  • Undergo skin ultrasound and routine laboratory testing
  • Allow photographs of affected skin areas to be taken
  • Return for follow-up assessments for up to 3 months

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Studietype

Observasjonsmessig

Registrering (Antatt)

80

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

  • Kina
    • Hunan
      • Changsha, Hunan, Kina, 410011
        • Rekruttering
        • Second Xiangya Hospital of Central South University
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen

Tar imot friske frivillige

Ja

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

The study population will include adults with hidradenitis suppurativa evaluated at the Department of Dermatology of the Second Xiangya Hospital of Central South University and age- and sex-matched healthy participants without hidradenitis suppurativa or other chronic skin diseases. Participants with hidradenitis suppurativa will be recruited from the dermatology outpatient population. A subgroup of participants with hidradenitis suppurativa who receive biologic or small-molecule therapy as part of routine clinical care will participate in the 3-month longitudinal follow-up component.

Beskrivelse

Inclusion Criteria:

For Participants With Hidradenitis Suppurativa:

  • Aged 18 to 45 years.
  • Diagnosed with hidradenitis suppurativa according to established clinical diagnostic criteria.
  • Able and willing to comply with the study procedures and follow-up assessments.
  • Able to provide written informed consent and willing to permit photography of affected skin areas.
  • No coexisting systemic lupus erythematosus, dermatomyositis, atopic dermatitis, steroid-dependent dermatitis, or other relevant skin diseases.
  • No use of biologic or small-molecule therapy that may affect hidradenitis suppurativa symptoms within 3 months before enrollment.
  • Right-handed according to the Edinburgh Handedness Inventory.

For Healthy Participants:

  • Aged 18 to 55 years.
  • No hidradenitis suppurativa or other chronic skin disease.
  • No chronic pain disorder.
  • No major neurological or psychiatric disorder.
  • Right-handed according to the Edinburgh Handedness Inventory.
  • Able to provide written informed consent and comply with the study procedures.

For the Longitudinal Treatment Cohort:

  • Meets the eligibility criteria for participants with hidradenitis suppurativa.
  • Is scheduled to receive biologic or small-molecule therapy for hidradenitis suppurativa as part of routine clinical care, as determined by the treating physician.
  • Willing and able to complete assessments before treatment and during 3 months of follow-up.

Exclusion Criteria:

  • Participation in another investigational drug study within 1 month before enrollment.
  • Alcohol or drug abuse or dependence within the previous 3 months.
  • Current use of medications that may lower the seizure threshold or current use of antidepressant medication.
  • Previous or current treatment with electroconvulsive therapy, vagus nerve stimulation, or transcranial magnetic stimulation.
  • Serious cardiac, hepatic, pulmonary, renal, thyroid, hematologic, or other systemic disease; malignant tumor; or another clinically significant abnormality that, in the investigator's judgment, makes participation inappropriate.
  • Pregnancy or breastfeeding.
  • Schizophrenia, bipolar disorder, or another major psychiatric disorder.
  • A neurological condition that may interfere with participation or interpretation of the imaging results, including markedly elevated intracranial pressure, intracranial vascular lesions, impaired consciousness, or inability to cooperate with study procedures.
  • Any contraindication to magnetic resonance imaging, including intracranial metallic foreign bodies, cardiac pacemakers, incompatible vascular or cardiac implants, or claustrophobia.
  • Inability to remain still or comply with resting-state functional magnetic resonance imaging procedures.
  • Unwillingness to allow study data to be collected.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
HS Cross-Sectional Cohort
Adults with hidradenitis suppurativa who participate in the cross-sectional comparison with healthy participants. They will undergo baseline clinical assessments, questionnaires, skin ultrasound, laboratory testing, and resting-state functional magnetic resonance imaging.
HS Longitudinal Treatment Cohort
A subgroup of adults with hidradenitis suppurativa who receive biologic or small-molecule therapy as part of routine clinical care. Participants will undergo assessments before treatment and during 3 months of follow-up, including repeat resting-state functional magnetic resonance imaging at month 3.
Biologisk: Routine Biologic Therapy for Hidradenitis Suppurativa
Biologic therapy is prescribed by the treating physician as part of routine clinical care and is not assigned by the study protocol. The study observes changes in clinical outcomes and resting-state brain activity before treatment and during 3 months of follow-up.
Healthy Participants
Age- and sex-matched healthy adults without hidradenitis suppurativa, other chronic skin diseases, chronic pain disorders, or major neurological or psychiatric disorders.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Between-Group Difference in Amplitude of Low-Frequency Fluctuation Derived From Resting-State fMRI at Baseline
Tidsramme: At baseline during a single resting-state fMRI visit
Whole-brain amplitude of low-frequency fluctuation (ALFF) values will be derived from resting-state blood-oxygen-level-dependent functional magnetic resonance imaging. ALFF reflects the amplitude of spontaneous low-frequency fluctuations in the blood-oxygen-level-dependent signal. Voxel-wise ALFF values will be compared between participants with hidradenitis suppurativa and healthy participants.
At baseline during a single resting-state fMRI visit
Between-Group Difference in Fractional Amplitude of Low-Frequency Fluctuation Derived From Resting-State fMRI at Baseline
Tidsramme: At baseline during a single resting-state fMRI visit
At baseline during a single resting-state fMRI visit
Between-Group Difference in Regional Homogeneity Derived From Resting-State fMRI at Baseline
Tidsramme: At baseline during a single resting-state fMRI visit
At baseline during a single resting-state fMRI visit
Between-Group Difference in Seed-Based Functional Connectivity Derived From Resting-State fMRI at Baseline
Tidsramme: Correlations between the mean time series of selected seed regions and predefined brain regions will be calculated and transformed into standardized connectivity values.
Correlations between the mean time series of selected seed regions and predefined brain regions will be calculated and transformed into standardized connectivity values.

Sekundære resultatmål

Resultatmål
Tidsramme
Change From Baseline in ALFF Derived From Resting-State fMRI at Month 3
Tidsramme: Baseline and 3 months after initiation of routine therapy
Baseline and 3 months after initiation of routine therapy
Change From Baseline in fALFF Derived From Resting-State fMRI at Month 3
Tidsramme: Baseline and 3 months after initiation of routine therapy
Baseline and 3 months after initiation of routine therapy
Change From Baseline in ReHo Derived From Resting-State fMRI at Month 3
Tidsramme: Baseline and 3 months after initiation of routine therapy
Baseline and 3 months after initiation of routine therapy
Change From Baseline in Seed-Based Functional Connectivity Derived From Resting-State fMRI at Month 3
Tidsramme: Baseline and 3 months after initiation of routine therapy
Baseline and 3 months after initiation of routine therapy

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Second Xiangya Hospital of Central South University

Etterforskere

  • Hovedetterforsker: Yi Zhan, Second Xiangya Hospital of Central South University

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

3. januar 2026

Primær fullføring (Antatt)

1. januar 2027

Studiet fullført (Antatt)

1. januar 2027

Datoer for studieregistrering

Først innsendt

4. august 2026

Først innsendt som oppfylte QC-kriteriene

4. august 2026

Først lagt ut (Faktiske)

10. august 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

10. august 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

4. august 2026

Sist bekreftet

1. august 2026

Mer informasjon

Begreper knyttet til denne studien

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • LYF20250311

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere